Apr 12, 2024, 14:08
Erman Akkus: Pancreatic cancer clinical trials in AACR24
Erman Akkus, Medical Oncology Fellow at Ankara University, shared on X:
“Pancreatic cancer clinical trials in AACR24:
- CT022 – Mutant KRAS peptide-based vaccine in patients at high risk of developing pancreatic cancer. mKRAS-specific T cell response induced.
- CT134 – Neoadjuvant/adjuvant GM-CSF-secreting allogeneic pancreatic tumor cell vaccine (GVAX) combined with cyclophosphamide, pembrolizumab, and macrophage-targeting CSF1R inhibitor IMC-CS4. Safe and significantly increased activated CD8+ T cells.
- CT025 – Personalized RNA neoantigen vaccines (autogenous cerumen). Induces polyfunctional CD8+ T effector cells of significant longevity, substantial magnitude, and durable function.
- CT031 -Neoadjuvant modified FOLFIRINOX plus nivolumab in borderline resectable pancreas cancer. Favorable rates of R0 resection, PFS, and OS.
- CT016 -Entinostat plus nivolumab. Immunomodulation of myeloid cell populations
- CT080 / 7 -Devimistat plus chemoradiation in inoperable pancreatic cancer. Safe and well tolerated, trial in progress.
- CT106 / 14 – Paclitaxel-eluting PTM-101 film in borderline resectable or locally advanced pancreatic cancer. Surgically feasible, safe, resulted in no systemic paclitaxel exposure, and caused a tumor size reduction.
- CT107 / 15 – Lymph node targeted mKRAS-specific amphiphile vaccine. Durable immunogenicity.
- Siltuximab plus spartalizumab in advanced pancreatic cancer. Safe but did not elicit responses.
- CT214 / 14 – Paricalcitol plus chemotherapy in metastatic pancreatic cancer. Limited clinical benefit.
- Minnelid in chemotherapy-refractory metastatic pancreatic cancer. Safe but did not elicit responses.
- Narmafotinib plus gemcitabine and nab-paclitaxel as first-line therapy in patients with advanced pancreatic cancer (ACCENT trial). Safe and PR in 47% of patients.”
Source: Erman Akkus/X
AACR24
ACCENT trial.
Adjuvant
Amphiphile vaccine
Ankara University
Autogenous cerumen
cancer
chemoradiation
chemotherapy
clinical trials
Devimistat
Entinostat
Erman Akkus
FOLFIRINOX
Gemcitabine
GM-CSF-secreting allogeneic pancreatic tumor cell vaccine
GVAX
IMC-CS4
Lymph node targeted
Macrophage-targeting CSF1R inhibitor
Medical Oncology Fellow
Minnelid
mKRAS-specific T cell response
Mutant KRAS peptide-based vaccine
nab-paclitaxel
Narmafotinib
Neoadjuvant
nivolumab
OncoDaily
Oncology
Pancreatic Cancer
Paricalcitol
pembrolizumab
Personalized RNA neoantigen vaccines
PTM-101 film
Siltuximab
Spartalizumab
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 7, 2024, 19:43
Dec 7, 2024, 19:32
Dec 7, 2024, 16:59
Dec 7, 2024, 16:59
Dec 7, 2024, 16:57
Dec 7, 2024, 16:57
Dec 7, 2024, 16:57
Dec 7, 2024, 16:57
Dec 7, 2024, 16:57